Merck & Co., Inc. operates as a healthcare company ... and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting ...

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, N.J. – Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania ...

lower sales of the COVID-19 medication LAGEVRIO, lower sales of GARDASIL/GARDASIL 9 and lower sales of SIMPONI and REMICADE, reflecting the transfer of marketing rights in former Merck territories ...

Merck has shipped around 6.4 million courses of Lagevrio around the world to date, showing strong demand outside the US, but is expecting sales of the drug going forward to be weaker than expected.

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

The underlying core business looks solid, with operational sales growth of 8% (excluding Lagevrio), led by cancer drug Keytruda (up 17%). Merck’s steady pipeline innovation, especially the ...

Molnupiravir is under clinical development by Merck and currently in Phase I for Liver Failure ... role in drug-specific PTSR and likelihood of approval. Molnupiravir (Lagevrio, Lizuvira) is a potent ...

Now there’s a new one for the list: cancer prevention vaccines. Merck, which makes the commonly used Gardasil shot, has shed 14 per cent of its market value since announcing last week that it ...